Drug Trial Radar · NCT00949624
CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 19, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Dec 2005
Primary completion
Jun 2008
Study completion Jun 2008
Sponsor
- Lead sponsor
- Arog Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 30, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A5301005 is a phase 1 study in patients with solid tumors which is testing the safety and tolerability of adding targeted agents to a standard chemotherapy. CP-868,596 is a platelet-derived growth factor receptor inhibitor (PDGFR) and AG-13736 is a vascular endothelial growth factor receptor inhibitor (VEGFR). This study will test the use of docetaxel (the standard chemotherapy) with either CP-868,596 or the combination of CP-868,596 and AG-13736.
Conditions
- Advanced Solid Tumors
Interventions
CP-868,596Drug
Oral tablet 60 mg BID continuous
DocetaxelDrug
Intravenous 75 mg/m2 every three weeks
CP-868,596Drug
Oral tablet 100 mg BID continuous
DocetaxelDrug
Intravenous 75 mg/m2 every three weeks
CP-868,596Drug
Oral tablet 100 mg BID continuous
DocetaxelDrug
Intravenous 100 mg/m2 every three weeks
CP-868,596Drug
Oral tablet 60 mg BID continuous
AG-013736Drug
Oral tablet 5 mg BID continuous
DocetaxelDrug
Intravenous 75 mg/m2 every three weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- First-cycle Dose Limiting ToxicitiesTime frame: 2.5 years
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Durham, North Carolina
Pfizer Investigational Site
East Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.